Rhone Ma Holdings Berhad (RHONEMA) Stock Overview
An investment holding company, engages in the manufacture, trading, marketing, and distribution of biotechnology and animal health products primarily in Malaysia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
RHONEMA Community Fair Values
See what others think this stock is worth. Follow their fair value or set your own to get alerts.
Rhone Ma Holdings Berhad Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | RM 0.70 |
| 52 Week High | RM 0.73 |
| 52 Week Low | RM 0.58 |
| Beta | 0.32 |
| 1 Month Change | 5.26% |
| 3 Month Change | 11.11% |
| 1 Year Change | 1.45% |
| 3 Year Change | 1.45% |
| 5 Year Change | 14.75% |
| Change since IPO | -11.49% |
Recent News & Updates
Rhone Ma Holdings Berhad (KLSE:RHONEMA) Has Affirmed Its Dividend Of MYR0.01
Jun 17Rhone Ma Holdings Berhad (KLSE:RHONEMA) Will Pay A Dividend Of MYR0.01
Apr 17Recent updates
Shareholder Returns
| RHONEMA | MY Pharmaceuticals | MY Market | |
|---|---|---|---|
| 7D | 2.9% | -0.01% | -0.4% |
| 1Y | 1.4% | -5.0% | 0.04% |
Return vs Industry: RHONEMA exceeded the MY Pharmaceuticals industry which returned -5% over the past year.
Return vs Market: RHONEMA exceeded the MY Market which returned 0% over the past year.
Price Volatility
| RHONEMA volatility | |
|---|---|
| RHONEMA Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in MY Market | 11.3% |
| 10% least volatile stocks in MY Market | 2.4% |
Stable Share Price: RHONEMA has not had significant price volatility in the past 3 months compared to the MY market.
Volatility Over Time: RHONEMA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 205 | I-Ie Lim | www.rhonema.com |
Rhone Ma Holdings Berhad, an investment holding company, engages in the manufacture, trading, marketing, and distribution of biotechnology and animal health products primarily in Malaysia. The company provides diagnostic laboratory analysis and consultation services to veterinary, agriculture, and food industries; tests and diagnostics services for human healthcare; and veterinary advisory services. It also conducts research and development in biotechnology; distributes human healthcare and related products; wholesales and distributes pharmaceutical and veterinary products, including animal feeds; undertakes research and development activities related to animal health, food safety, and agriculture; and distributes and supplies food ingredients.
Rhone Ma Holdings Berhad Fundamentals Summary
| RHONEMA fundamental statistics | |
|---|---|
| Market cap | RM 154.09m |
| Earnings (TTM) | RM 13.16m |
| Revenue (TTM) | RM 207.99m |
Is RHONEMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RHONEMA income statement (TTM) | |
|---|---|
| Revenue | RM 207.99m |
| Cost of Revenue | RM 143.88m |
| Gross Profit | RM 64.10m |
| Other Expenses | RM 50.95m |
| Earnings | RM 13.16m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.06 |
| Gross Margin | 30.82% |
| Net Profit Margin | 6.33% |
| Debt/Equity Ratio | 11.4% |
How did RHONEMA perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/01 19:43 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rhone Ma Holdings Berhad is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Public Investment Bank Berhad |
| Jia Loo | TA Securities Holdings Berhad |
